SIShogo Inoue

Shogo Inoue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shogo Inoue has a total of 159 co-authors. Here are the top co-authors by number of shared publications:

  • Akio Matsubara

    Department of Urology Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

    32 shared publications
  • Jun Teishima

    Department of Urology Kobe University Graduate School of Medicine Kobe Japan

    28 shared publications
  • Tetsutaro Hayashi

    Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan

    20 shared publications
  • Keisuke Hieda

    Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan

    17 shared publications
  • Jun Teishima

    Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan

    15 shared publications
  • Mitsuru Kajiwara

    Department of Urology Hiroshima Prefectural Hospital Hiroshima Japan

    11 shared publications

Latest Publications

  • Sequential Enzalutamide–Docetaxel Versus Abiraterone–Docetaxel Therapy in Castration‐Resistant Prostate Cancer: A Subanalysis of the ENABLE Study

    by Manabu Kamiyama, Kouji Izumi, Takahiko Mitsui, Takashi Shima, Yuki Kato, Koji Mita, Takehiko Okamura, Shogo Inoue, Seiji Hoshi, Nobumichi Tanaka, et al.

    Background: Docetaxel (DTX) is commonly employed in patients with castration‐resistant prostate cancer (CRPC) following failure of androgen receptor signaling inhibitors (ARSIs). However, the impact of prior ARSI treatment on the efficacy of subsequent DTX therapy remains unclear. This study aimed to compare oncological outcomes between enzalutamide (ENZ)–DTX and abiraterone acetate plus prednisolone (ABI)–DTX sequential treatment strategies in patients with CRPC. Methods: The ENABLE study for PCa was an investigator‐initiated, multicenter, randomized controlled trial conducted in Japan to compare ENZ and ABI. This subanalysis evaluated the efficacy of subsequent DTX therapy in patients who had received either ENZ or ABI. Results: Between February 2015 and July 2019, 203 patients were enrolled, of whom 184 were randomized to receive ENZ or ABI (92 per arm). Among them, 20 and 21 patients subsequently initiated DTX therapy following ENZ and ABI, respectively. Median prostate cancer‐specific survival (PCSS) in the ENZ–DTX and ABI–DTX groups was 22.7 and 32.1 months, respectively ( p = 0.1724). Median PCSS from the initiation of DTX was 16.1 months in the ENZ–DTX group and 25.3 months in the ABI–DTX group ( p = 0.0966). In the overall cohort ( n = 41), patients who received additional ARSIs after ARSI–DTX therapy had significantly longer PCSS from the initiation of DTX compared with those who did not (median 21.6 vs. 13.8 months, p = 0.0157). Conclusions: ENZ–DTX and ABI–DTX sequential therapies demonstrated comparable survival outcomes in patients with CRPC. Notably, the administration of additional ARSIs following ARSI–DTX therapy may confer a survival benefit, suggesting a potential role for continued ARSI use in this treatment sequence. Trial Registration: The trial was registered with the University Hospital Medical Information Network (UMIN) Center under the identifier UMIN000015529 on November 1, 2014

  • Open Access

    Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma

    by Jun Teishima, Daiki Murata, Kazuma Yukihiro, Yohei Sekino, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, et al.

    Objectives: This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma. Marterials and methods: Fifty-eight patients with metastatic renal cell carcinoma treated with nivolumab monotherapy were retrospectively studied. Patients who were treated with nivolumab as second-line therapy were included in the second-line group, while the others were included in the later-line group. The clinicopathological characteristics, effects of nivolumab, and prognoses of these groups were compared. Results: Twenty and thirty-eight patients were included in the second-line and later-line groups, respectively. There were no significant differences in the distribution of International Metastatic Renal Cell Carcinoma Database Consotium risk and other clinicopathological characteristics between the 2 groups. The proportion of patients whose objective best response was progressive disease in the second-line group was significantly lower than that in the later-line group (15% vs. 50%, p = 0.0090). The 50% progression-free survival with nivolumab in the second-line group was significantly better than that in the later-line group (not reached and 5 months, p = 0.0018). Multivariate analysis showed that the second-line setting was an independent predictive factor for better progression-free survival ( p = 0.0028, hazard ratio = 0.108). The 50% overall survival after starting nivolumab in the second-line and later-line groups was not reached and 27.8 months, respectively ( p = 0.2652). Conclusions: The therapeutic efficacy of nivolumab as second-line therapy is expected to be better than that of later therapy.


  • Longitudinal analysis of retroperitoneoscopic adrenalectomy regarding cosmesis outcomes: comparison of lateral transperitoneal and reduced port laparoscopic adrenalectomy

    by Shogo Inoue, Keisuke Goto, Kenichiro Ikeda, Keisuke Hieda, Tetsutaro Hayashi, Jun Teishima

    The aim of this study is to compare patient-reported cosmesis and satisfaction outcomes between lateral retroperitoneoscopic adrenalectomy (LRA), laparoendoscopic single site and reduced port adrenalectomy (LESS/RP-A) and lateral transperitoneal laparoscopic adrenalectomy (LTA). A total of 26, 86 and 50 patients who underwent LRA, LESS/RP-A and LTA were included in the study. All LESS/RP-A cases were performed taking the transumbilical approach. We mailed a questionnaire to all patients 1, 3, 6, 9 and 12 months after operation. Questionnaires inquiring about cosmesis (0: very ugly, 10: very beautiful) on the basis of a visual analogue scale were administered. The mean scores of cosmesis at postoperative months 1, 3, 6, 9 and 12 were 7.11, 7.00, 6.57, 5.25 and 5.46 for the LRA group, 8.43, 8.86, 8.95, 8.46 and 9.09 for the LESS/RP-A group and 7.18, 7.74, 7.58, 7.44 and 8.09 for the LTA group. The difference in cosmesis score between the LRA and LESS/RP-A groups gradually increased after surgery, and the cosmesis score for the LRA group was significantly lower at every postoperative point. The difference in cosmesis score between the LRA and LTA groups gradually increased after surgery, and the cosmesis score for the LRA group was significantly lower at postoperative months 9 (p = 0.015) and 12 (p = 0.002). This study is the first comprehensive longitudinal analysis of patient-reported cosmesis outcomes between LRA, LESS/RP-A and LTA. LRA was the surgical procedure that resulted in lower cosmesis scores when compared with those following the LESS/RP-A and LTA procedures.


  • Open Access

    HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer

    by Yohei Sekino, Quoc Thang Pham, Kohei Kobatake, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Shogo Inoue, Tetsutaro Hayashi, Masaki Shiota, Wataru Yasui, et al.

    Homeobox genes function as master regulatory transcription factors during embryogenesis. HOXB5 is known to play an important role in several cancers. However, the biological role of HOXB5 in prostate cancer (PCa) is not fully elucidated. This study aimed to analyze the expression and function of HOXB5 and involvement of HOXB5 in neuroendocrine differentiation in PCa. Immunohistochemistry showed that 56 (43.8%) of 128 cases of localized PCa were positive for HOXB5. HOXB5-positive cases were associated with poor prostate-specific antigen recurrence-free survival after prostatectomy. Among 74 cases of metastatic PCa, 43 (58.1%) were positive for HOXB5. HOXB5 expression was higher in metastatic PCa than that in localized PCa. HOXB5 knockdown suppressed cell growth and invasion, but HOXB5 overexpression increased cell growth and invasion in PCa cell lines. Furthermore, HOXB5 regulated RET expression. Gene set enrichment analysis revealed that Nelson androgen response gene set was enriched in low HOXB5 expression group. RB1 knockout increased HOXB5 expression. Of note, additional p53 knockdown further increased HOXB5 expression in RB1 knockout cells. In silico analysis showed that HOXB5 expression was increased in neuroendocrine PCa (NEPC). These results suggest that HOXB5 may be a promising prognostic marker after prostatectomy and is involved in progression to NEPC.


  • Tumor contact length of prostate cancer determined by a three‐dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence

    by Shunsuke Miyamoto, Keisuke Goto, Yukiko Honda, Hiroaki Terada, Shinsuke Fujii, Takeshi Ueno, Kenichiro Fukuoka, Yohei Sekino, Hiroyuki Kitano, Kenichiro Ikeda, et al.

    Objective: To evaluate the clinical benefit of tumor contact length as a predictor of pathological extraprostatic extension and biochemical recurrence in patients undergoing prostatectomy.Methods: A total of 91 patients who underwent 3T multiparametric magnetic resonance imaging before prostatectomy from April 2014 to July 2019 were included. A total of 94 prostate cancer foci were analyzed retrospectively. We evaluated maximum tumor contact length, which was determined to be the maximum value in the three‐dimensional directions, as a predictor of pathological extraprostatic extension and biochemical recurrence.Results: A total of 19 lesions (20.2%) had positive pathological extraprostatic extension. Areas under the curves showed maximum tumor contact length to be a significantly better parameter to predict pathological extraprostatic extension than the Prostate Imaging Reporting and Data System (P = 0.002), tumor maximal diameter (P = 0.001), prostate‐specific antigen (P = 0.020), Gleason score (P < 0.001), and clinical T stage (P < 0.001). Multivariate analysis showed maximum tumor contact length (P = 0.003) to be an independent risk factor for predicting biochemical recurrence. We classified the patients using preoperative factors (prostate‐specific antigen >10, Gleason score >3 + 4 and maximum tumor contact length >10 mm) into three groups: (i) high‐risk group (patients having all factors); (ii) intermediate‐risk group (patients having two of three factors); and (iii) low‐risk group (patients having only one or none of the factors). Kaplan–Meier curves showed that the high‐risk group had significantly worse biochemical recurrence than the intermediate‐risk group (P = 0.042) and low‐risk group (P < 0.001).Conclusions: Our findings suggest that maximum tumor contact length is an independent predictor of pathological extraprostatic extension and biochemical recurrence. A risk stratification system using prostate‐specific antigen, Gleason score and maximum tumor contact length might be useful for preoperative assessment of prostate cancer patients.


  • Open Access

    Postoperative around-the-clock administration of intravenous acetaminophen for pain control following robot-assisted radical prostatectomy

    by Shogo Inoue, Hirotsugu Miyoshi, Keisuke Hieda, Tetsutaro Hayashi, Yasuo M. Tsutsumi, Jun Teishima

    The objective of this study was to examine the impact of around-the-clock (ATC) administration of intravenous (IV) acetaminophen following robot-assisted radical prostatectomy (RARP). Intravenous infusion of acetaminophen was started on the day of the operation at 1000 mg/dose every 6 h, and the infusion was continued on a fixed schedule until postoperative day 2 a.m. In a retrospective observational study, we compared 127 patients who were administered IV acetaminophen on a fixed schedule (ATC group) with 485 patients who were administered analgesic drugs only as needed (PRN group). We investigated postoperative pain intensity and additional analgesic consumption on postoperative day 0, 1, 2, 3, and 5 between the two groups. Postoperative pain scores were significantly lower in the ATC group than in the PRN group at 1 and 2 days, and this period matched the duration of ATC administration of IV acetaminophen. Postoperative frequency of rescue analgesia was significantly lower in the ATC group than in the PRN group at postoperative 0, 1, and 2 days. ATC administration of IV acetaminophen has the potential to be a very versatile and valuable additional dose to achieve appropriate postoperative analgesia in patients with RARP.


  • Comparison of Chief Surgeons’ and Assistants’ Feelings of Fatigue Between Laparoendoscopic Single‐site and Conventional Laparoscopic Adrenalectomy

    by Shogo Inoue, Kenichiro Ikeda, Keisuke Goto, Keisuke Hieda, Tetsutaro Hayashi, Jun Teishima

    Background Our objective was to compare the surgical staff’s feelings of fatigue between laparoendoscopic single-site adrenalectomy (LESS-A) and conventional laparoscopic adrenalectomy (CLA) before and after surgery. Method Data were collected for surgical procedures performed between June 2011 and September 2017 (57 LESS-A and 37 CLA). Each procedure in both groups was performed by the same chief surgeon. The subjective fatigue feelings of the key members of the surgical team (chief surgeon, scopist, assistant surgeon) were assessed using the “Jikaku-sho shirabe” questionnaire, which contained questions about work-related feelings of fatigue. It consisted of 25 subjective items for 5 factors drawn from factor analysis (drowsiness, instability, uneasiness, local pain or dullness, and eyestrain). For each item, the participants were requested to estimate the intensity of their feelings using a five-point rating scale before and after surgery. Results There was no significant difference in operative time (p = 0.231) between the LESS-A and CLA procedure groups. For the chief surgeon, local pain or dullness (p = 0.603) and eyestrain (p = 0.086) were similar between the LESS-A and CLA procedures. The scopists and assistant surgeons in the LESS-A group did not suffer local pain or dullness (p = 0.793 and p = 0.240, respectively). They did, however, suffer more eyestrain than those in the CLA group (p = 0.001 and p = 0.001, respectively). Conclusion Although LESS-A is generally considered to be a technically difficult procedure, the results of this study demonstrate that the feelings of physical fatigue are roughly equivalent between LESS-A and CLA procedures.


  • Open Access

    Postoperative around-the-clock administration of intravenous acetaminophen for pain control following robot-assisted radical prostatectomy

    by Shogo Inoue, Hirotsugu Miyoshi, Keisuke Hieda, Tetsutaro Hayashi, Yasuo Tsutsumi, Jun Teishima

    The objective of this study was to examine the impact of around-the-clock (ATC) administration of intravenous (IV) acetaminophen following Robot-assisted radical prostatectomy (RARP). Intravenous infusion of acetaminophen was started on the day of the operation at 1000 mg/dose every 6 hours, and the infusion was continued on a fixed schedule until postoperative day 2 AM. We compared 127 patients who were administered IV acetaminophen on a fixed schedule (ATC group) with 485 patients who were administered analgesic drugs only as needed (PRN group). We investigated postoperative pain intensity and additional analgesic consumption on postoperative day 0, 1, 2, 3, and 5 between the two groups. Postoperative pain scores were significantly lower in the ATC group than in the PRN group at 1 and 2 days, and this period matched the duration of ATC administration of IV acetaminophen. Postoperative frequency of rescue analgesia was significantly lower in the ATC group than in the PRN group at postoperative 0, 1, and 2 days. ATC administration of IV acetaminophen has the potential to be a very versatile and valuable additional dose to achieve appropriate postoperative analgesia in patients with RARP.

  • Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve‐sparing robot‐assisted laparoscopic radical prostatectomy

    by Shogo Inoue, Testutaro Hayashi, Jun Teishima, Akio Matsubara

    Objective: To evaluate the frequency of sexual intercourse and sexual activity of patients after nerve‐sparing (NS) robot‐assisted laparoscopic radical prostatectomy (RARP). Patients and Methods: We prospectively obtained 2‐years longitudinal Expanded Prostate Cancer Index Composite (EPIC) and Sexual Health Inventory for Men (SHIM) score data from 99 patients. We classified the frequency of sexual intercourse and sexual activity as ‘none’, ‘less than once a week’, ‘about once a week’, ‘several times a week’, and ‘daily’. Results: The percentages of patients who took part in sexual activity before and at 3, 6, 9, 12, 18, and 24 months after NS RARP were 55.6%, 27.9%, 38.8%, 42.5%, 44.4%, 41.7%, and 42.1%, respectively. The percentages of patients who took part in sexual intercourse before and at 3, 6, 9, and 12, 18, and 24 months after NS RARP were 41.4%, 9.0%, 13.3%, 16.3%, 16.7%, 22.2%, and 23.7%, respectively. Preoperative sexual status was classified into two groups: those who had sexual intercourse or those who only had sexual activity except sexual intercourse. Sexual function (SF) was investigated longitudinally using the EPIC and SHIM data between the two groups. The SHIM data showed an improvement in SF in the sexual intercourse group, but did not do so in the sexual activity except sexual intercourse group. On the other hand, SF in the EPIC data might reflect the postoperative improvement of SF in the sexual activity except sexual intercourse group. Conclusion: There was a large discrepancy between the percentages of patients taking part in sexual intercourse and sexual activity; therefore, surveys of postoperative SF are recommended to include not only sexual intercourse but also sexual activity.


  • Longitudinal analysis of trifecta outcome in Japanese patients with prostate cancer following robot-assisted laparoscopic radical prostatectomy

    by Shogo Inoue, Keisuke Hieda, Testutaro Hayashi, Jun Teishima, Akio Matsubara

    Purpose To analyze the trifecta outcome (continence, potency, and cancer control) longitudinally using robot-assisted laparoscopic radical prostatectomy (RARP). Method We prospectively obtained 1-year longitudinal Expanded Prostate Cancer Index Composite (EPIC) data (preoperative and at 3, 6, 9, and 12 months after RARP) from 291 patients who underwent RARP by a single surgeon. Continence was defined as the use of ‘zero or one pads’. Potency was defined as the ability to achieve and maintain satisfactory erections firm enough for sexual activity or sexual intercourse. Continence and potency were subjectively determined from patient-reported outcomes (EPIC question nos. 5 and 18). The biochemical recurrence (BCR) rate was defined as two consecutive PSA levels of > 0.2 ng/mL after RARP. Outcomes of the pentafecta were complications and positive surgical margins combined with the trifecta outcomes. Results Trifecta was achieved in 4.6, 5.6, 8.1, and 9.6% of all patients at 3, 6, 9, and 12 months, respectively. Pentafecta rates were 2.3, 3.0, 5.1, and 6.1%, respectively. Trifecta rates in the nerve-sparing (NS) group were 12.5, 12.7, 18.9, and 23.6%, respectively. The BCR-free rates maintained a high level and were 94.4, 93.9, 93.9, and 90.9%, respectively. Continence rates were improved to 55.2, 75.5, 81.6, and 85.0%, while the potency rate was extremely low at 7.5, 7.8, 9.8, and 10.9%. Even in the NS group, potency rates remained low at 18.1, 18.6, 21.9, and 26.1%, respectively. Conclusion This longitudinal analysis of trifecta outcomes may be beneficial and should be used when counseling patients with clinically localized PCa.